Cell-based therapy for ischemic heart disease: a clinical update.
Progenitor cell therapy is a promising treatment for ischemic heart disease. Early clinical trials of autologous bone marrow-derived progenitor cell therapy for acute and chronic myocardial ischemia showed modest functional improvements after cell delivery; however, the duration of these benefits remains unclear. Ongoing investigations continue to enhance our understanding of the mechanisms by which progenitor and stem cells function and how their survival and cardioprotective abilities can be improved. This review discusses: (1) relevant progenitor and stem cells in myocardial regenerative therapy, (2) routes of cell delivery to ischemic myocardium, (3) clinical trials investigating bone marrow-derived progenitor cell therapy for myocardial ischemia, and (4) future directions of the field.
Clarian Cardiovascular Surgery, Indianapolis, Indiana, USA.
Jeremy L
JL
Herrmann
Aaron M
AM
Abarbanell
Brent R
BR
Weil
Yue
Y
Wang
Meijing
M
Wang
Jiangning
J
Tan
Daniel R
DR
Meldrum
D002986:Clinical Trials as Topic; D006801:Humans; D017202:Myocardial Ischemia / Q000601:surgery*; D033581:Stem Cell Transplantation